Home > Cardiology > AHA 2019 > Trials in Electrophysiology and Left Ventricular Function > Testosterone gel increases left ventricular mass

Testosterone gel increases left ventricular mass

Presented By
Dr Elizabeth Hutchins, UCLA, USA
AHA 2019
Testosterone Cardiovascular Trial
Dr Elizabeth Hutchins (UCLA, USA) reported the first-ever, double-blind, randomised controlled trial to measure the effect of testosterone therapy on left ventricular (LV) mass in humans. The multicentre, placebo-controlled Testosterone Cardiovascular Trial reported that treating hypogonadism in older men with testosterone gel boosted their LV mass by 3.5% within 1 year [1]. Dr Hutchins presented new findings on the effect of treatment with 1% topical testosterone gel (AndroGel) on body surface area–indexed LV mass. Men over the age of 65 with low serum testosterone (n=123) were randomised to apply either testosterone gel or placebo. Coronary CT angiography was performed at baseline, and again after 1 year. The study cohort was complex and had significant comorbidities; >80% of the men were above age 75, half were obese, >65% had hypertension, and 30% had diabetes. Serum testosteron...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on